Aarey Drugs Allots 25.2 Lakh Equity Shares on Warrant Conversion
Aarey Drugs & Pharmaceuticals Limited approved the allotment of 25,20,000 equity shares upon conversion of warrants. This conversion raised ₹12.06 crore. The company's issued and paid-up capital increased to ₹33.35 crore. 24,80,000 warrants remain outstanding.
The conversion of warrants increases the company's equity base and raises capital, which can have a medium-term impact on its financial structure and growth prospects. However, the amount raised is not exceptionally large in the context of the overall market.
The company has successfully converted warrants into equity shares, raising capital and increasing its paid-up capital, which is generally a positive development.
Aarey Drugs & Pharmaceuticals Limited has announced the outcome of its Board Meeting held on August 6, 2026. The board approved the allotment of 25,20,000 Equity Shares of face value ₹10 each, pursuant to the conversion of fully convertible warrants.
These warrants were initially issued on a preferential basis at an offer price of ₹63.80 per warrant. The conversion into equity shares occurred upon receipt of ₹47.85 per warrant, representing 75% of the issue price. The total amount raised from this conversion is ₹12,05,82,000.
Following this allotment, the company's issued and paid-up capital has increased. The issued capital now stands at ₹33,35,43,030 represented by 3,33,54,303 shares, and the paid-up capital is also ₹33,35,43,030 represented by 3,33,54,303 shares.
Out of the total 50,00,000 convertible warrants initially allotted on May 23, 2025, 25,20,000 warrants have been converted into equity shares. The remaining 24,80,000 warrants are still outstanding. The tenure for conversion of these warrants into equity shares is 18 months from the allotment date, which was May 23, 2025.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.